{"Clinical Trial ID": "NCT01008150", "Intervention": ["INTERVENTION 1:", "1st arm : Paclitaxel + Trastuzumab then A C", "4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. Trastuzumab at the same time as paclitaxel weekly for a total of 16 doses (4 mg/kg load dose, then 2 mg/kg per week). After paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles.", "- Paclitaxel", "- Trastuzumab", "Doxorubicin", "- Cyclophosphamide", "INTERVENTION 2:", "Bras 2: Paclitaxel + Neratinib then A C", "\u00b7 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. Neratinib 240 mg orally once daily from day 1 of paclitaxel and continue until day 28 of the final cycle of paclitaxel. After paclitaxel/neratinib treatment, standard AC every 21 days for 4 cycles. After surgery, trastuzumab (8 mg/kg charge dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted treatment (i.e. preoperative treatment with trastuzumab or neratinib)", "- Paclitaxel", "Neratinib", "Doxorubicin", "- Cyclophosphamide"], "Eligibility": ["Incorporation criteria:", "Patients should have a life expectancy of at least 10 years, excluding their diagnosis of breast cancer.", "The presentation of a block of the diagnostic biopsy sample and the surgical sample, if a raw residual disease greater than or equal to 1.0 cm has been eliminated at the time of the intervention, is required for all patients.", "Patients with reproductive potential should agree to use an effective non-hormonal contraceptive method during treatment and for at least 6 months after the last study dose.", "The performance status of the Eastern Cooperative Oncology Group (ECOG) must be 0 or 1.", "Patients should have the ability to swallow oral medicines.", "The diagnosis of invasive breast adenocarcinoma should have been made either by the heart biopsy of the needle or by a limited incisional biopsy.", "If the ER analysis is negative, then analysis of the progesterone receptor (PgR) should also be performed. (Patients are eligible with either positive or negative hormonal hormonal tumours.)", "Breast cancer should be determined as HER2-positive prior to randomization. FISH or CISH analyses require gene amplification. IHC analyses require a highly positive coloring score (3+).", "The clinical stage, based on the physical examination assessment, must be stage IIB, IIIA, IIIB or IIIC of the U.S. Joint Committee on Cancer (JJCC): cT2 and cN1; cT3 and cN0 or cN1; cT and cN2 or cN3; or cT4", "The patient should have a mass in the breast or axilla of 2.0 cm or greater by physical examination, unless the patient has inflammatory breast cancer, in which case a disease measurable by physical examination is not necessary.", "At the time of randomisation, blood counts performed within 4 weeks prior to randomization should meet the following criteria: absolute neutrophil counts (NPCs) should be greater than or equal to 1200/mm3; platelet counts should be greater than or equal to 100,000/mm3; haemoglobin should be greater than or equal to 10 g/dL", "Total bilirubin should be less than or equal to the upper limit of normal (ULN) for the laboratory, unless the patient has an elevation of bilirubin greater than ULN at 1.5 x ULN due to Gilbert's disease or a similar syndrome involving slow bilirubin conjugation; and alkaline phosphatase should be less than or equal to 2.5 x ULN for the laboratory; and aspartate aminotransferase (AST) and ALT should be less than or equal to 1.5 x ULN for the laboratory.", "Patients with alkaline phosphatase greater than ULN but less than or equal to 2.5 x ULN may be included in the study if liver imaging (CT, MRI, PET or TEP-CT) performed within 4 weeks prior to randomization does not demonstrate metastatic disease and if the requirements for adequate liver function are met.", "Patients with unexplained skeletal pain or alkaline phosphatase greater than ULN but less than or equal to 2.5 x ULN may be included in the study if a bone scan, TEP-CT scan or TEP scan performed within 4 weeks prior to randomization does not demonstrate metastatic disease.", "The serum creatinine administered within 4 weeks prior to randomization should be less than or equal to 1.5 x ULN for the laboratory.", "The evaluation of the left ventricular ejection fraction (VEF) by 2-D echocardiogram or multiple acquisition scan (MUGA) performed within 90 days prior to randomization must be greater than or equal to 50%, regardless of the LLN of the installation.", "- Exclusion criteria:", "Only aspiration for fine needs (AFN) can diagnose primary breast cancer.", "A biopsy excision or a lumpectomy performed prior to randomization.", "(Pre-study procedures include: 1) RNA or axillary node nucleus biopsy for any patient, and 2) although not recommended, preneoadjuvant NS biopsy for patients with clinically negative axillary nodes.)", "(Note: Thoracic imaging [mandatory for all patients] and other imaging [if necessary] must have been performed within 90 days prior to randomization.)", "The history of ipsilateral invasive breast cancer, regardless of treatment or ipsilateral in situ channel carcinoma (IDC) treated with radiotherapy (RT). (Patients with a history of LCIS are eligible.)", "Patients with contralateral DCIS or lobular carcinoma in situ (LCIS) are eligible.)", "\u2022 History of non-brain malignancies (except for in situ cancers treated only by local excision and basal cell and squamous skin carcinomas) within 5 years of randomization.", "A known metastatic disease of any tumour (solid or haematological tumour).", "Previous treatment with anthracyclines, taxanes, cyclophosphamide, trastuzumab or neratinib for any malignancy.", "Treatment including RT, chemotherapy and/or targeted treatment for breast cancer currently diagnosed prior to randomisation.", "\u2022 Continuous endocrine therapy such as raloxifene or tamoxifen (or another SERM) or aromatase inhibitor. (Patients are eligible if these drugs are discontinued prior to randomization.)", "Any ongoing sexual hormonal therapy, e.g. contraceptive pills and replacement ovary hormone therapy. Patients are eligible if these drugs are discontinued prior to randomization.", "Hepatitis B is active or hepatitis C with abnormal liver function tests.", "Intrinsic lung disease leading to dyspnoea.", "\u2022 Active infection or chronic infection requiring chronic suppressive antibiotics.", "\u2022 Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, small stomach or intestine resection, or any other disease or condition significantly affecting gastrointestinal function.", "Resistant to grade 2 diarrhea, regardless of etiology.", "A sensory or motor neuropathy greater than or equal to Class 2, as defined by the Common Criteria for the Toxicity of NCI to Adverse Reactions (CTCAE) v3.0.", "Conditions that would prohibit intermittent administration of corticosteroids for premedication of paclitaxel.", "- Chronic daily corticosteroid treatment with a dose greater than or equal to 10 mg/day of methylprednisolone equivalent (excluding inhaled steroids).", "- Uncontrolled hypertension defined as systolic PB greater than 150 mmHg or diastolic PB greater than 90 mmHg, with or without antihypertensive drugs. (Patients with hypertension that is well controlled by drugs are eligible.)", "- Cardiac disease (history and/or active disease) that would prevent the use of any of the medicines included in the regimen, including, but not limited to, active heart disease: symptomatic angina in the last 180 days requiring the initiation or increase of an anti-anginary medication or other intervention; ventricular arrhythmias, except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a heart pacemaker or not controlled by a drug; conduction abnormality requiring a heart pacemaker; valvular disease with documented compromise in cardiac function; and symptomatic pericarditis.", "Another non-malignant systemic disease that would prevent the patient from receiving study treatment or prevent the necessary follow-up.", "\u2022 Pregnancy or lactation at randomisation.", "The investigator must evaluate the patient to determine whether she is suffering from a psychiatric disorder, addiction or other condition that, in the opinion of the investigator, would prevent her from meeting the requirements of the study.", "The use of any research officer within 4 weeks of randomization."], "Results": ["Performance measures:", "- Complete pathological response in the breast and axillary glands.", "Number of participants with no histological evidence of invasive tumour cells in the surgical breast sample, axillary lymph nodes after neoadjuvant chemotherapy", "Time limit: At the time of surgery, about 7 months", "Results 1:", "Title of arm/group: Arm 1: Paclitaxel + Trastuzumab then A C", "Description of the arm/group: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. Trastuzumab at the same time as the weekly paclitaxel for a total of 16 doses (4 mg/kg load dose, then 2 mg/kg per week). After paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles.", "- Paclitaxel", "- Trastuzumab", "Doxorubicin", "- Cyclophosphamide", "Total number of participants analysed: 42", "Type of measure: Number of participants", "Unit of measure: Participants 16 38.1%", "Results 2:", "Title of arm/group: Arm 2: Paclitaxel + Neratinib then A C", "\u00b7 Arm/group description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. Neratinib 240 mg orally once daily from day 1 of paclitaxel and continue until day 28 of the final cycle of paclitaxel. After paclitaxel/neratinib treatment, standard AC every 21 days for 4 cycles. After surgery, trastuzumab (8 mg/kg charge dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted treatment (i.e. preoperative trastuzumab treatment or neratinib treatment)", "- Paclitaxel", "Neratinib", "Doxorubicin", "- Cyclophosphamide", "Total number of participants analysed: 42", "Type of measure: Number of participants", "Unit of measure: Participants 14 33.3%"], "Adverse Events": ["Undesirable Events 1:", "Total: 7/42 (16.67%)", "Febrile neutropenia 1/42 (2.38%)", "- Left venous dysfunction 1/42 (2.38 per cent)", "Cardiac valve disease 1/42 (2.38%)", "Diarrhoea 0/42 (0.00 %)", "Abdominal pain 1/42 (2.38%)", "- Collite 0/42 (0.00 per cent)", "- Nausea 0/42 (0.00 %)", "- Vomiting 0/42 (0.00 %)", "Pyrexia 0/42 (0.00 %)", "1/42 (2.38%)", "Peripheral edema 1/42 (2.38%)", "Fatigue 0/42 (0.00 %)", "Adverse Events 2:", "Total: 7/42 (16.67%)", "- Febrile neutropenia 0/42 (0.00 %)", "- Left venous dysfunction 1/42 (2.38 per cent)", "Cardiac valve disease 0/42 (0.00 %)", "Diarrhoea 0/42 (0.00 %)", "Abdominal pain 0/42 (0.00 %)", "- Collite 0/42 (0.00 per cent)", "- Nausea 0/42 (0.00 %)", "- Vomiting 0/42 (0.00 %)", "Pyrexia 2/42 (4.76%)", "- Influenza syndrome 0/42 (0.00 %)", "Peripheral edema 0/42 (0.00 %)", "Fatigue 0/42 (0.00 %)"]}